Screener
Eton Pharmaceuticals, Inc. ETON EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | For the three months ended / March 31, 2026 | For the three months ended / March 31, 2025 |
|---|---|---|
| Interest and other expense, net | (840) | (1,028) |
| Income (loss) before income tax expense | 1,574 | (1,498) |
| Income tax expense | 20 | 74 |
| Net income (loss) | $1,554 | $(1,572) |
| Net income (loss) per share, basic | $0.06 | $(0.06) |
| Weighted average number of common shares outstanding, basic | 27,285 | 26,886 |
| Net income (loss) per share, diluted | $0.05 | $(0.06) |
| Weighted average number of common shares outstanding, diluted | 31,547 | 26,886 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s EPS (diluted)?
- Eton Pharmaceuticals, Inc. (ETON) reported EPS (diluted) of $0.05 in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Eton Pharmaceuticals, Inc.'s EPS (diluted) increased by 183.3% year-over-year, from -$0.06 to $0.05.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Eton Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude